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Abstract 
Aims –Evaluation of the possible relationship between pharmacokinetics and the safety 
of aripiprazole, and its influence on blood pressure, heart rate and corrected QT (QTc) 
interval. Materials and Methods – The study population comprised 157 healthy 
volunteers from 6 bioequivalence clinical trials. Subjects were administered a single 10-
mg oral dose of each formulation separated by a 28-days washout period. Plasma 
concentrations were measured using high performance liquid chromatography coupled to 
mass spectrometry. Blood pressure was measured at the following times: pre-dose and 
0.5, 2, 4, 6 and 8 hours post-dose. An electrocardiogram (ECG) was recorded at pre-dose, 
4 and 8 hours post-dose. Results –AUC, Cmax, T1/2 and Vd/W were higher in women. 
Aripiprazole treatment produced a decrease of blood pressure (9.3 mmHg on systolic and 
6.2 mmHg on diastolic pressure) and an increase in heart rate (12.1 bpm) and QTc interval 
(9.1 ms). There were sex differences in blood pressure, heart rate and QTc interval. 
Women and subjects with higher AUC and Cmax values were more prone to suffer adverse 
drug reactions (ADRs) and gastrointestinal adverse reactions. AUC was related with 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) decrease and heart rate 
(HR) increase but there was no relationship between aripiprazole concentrations and QTc 
increase. 
Conclusions – Aripiprazole decreases blood pressure and increases heart rate and QTc 
interval. Pharmacokinetics, pharmacodynamics and safety of aripiprazole are affected by 
sex. There is a directly proportional relationship between pharmacokinetic parameters 
and ADRs and effect on BP and HR. 
Key words: aripiprazole; pharmacokinetics; pharmacodynamics; safety. 
Tables included: 4 
Figures included: 1 
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Introduction 
Aripiprazole is an atypical antipsychotic indicated for the treatment of schizophrenia and 
manic or mixed episodes associated with bipolar I disorder. The recommended dose for 
patients with schizophrenia is 10-15 mg/day and for patients with manic episodes is 15 
mg/day (1, 2). 
Due to its mechanism of action aripiprazole belongs to a new generation of antipsychotics 
called “third-generation” antipsychotics (3). It acts as a partial agonist of the dopamine 
D2, dopamine D3 and serotonin 5-HT1A receptors and as an antagonist of the serotonin 5-
HT2A and 5-HT7 receptors (4, 5, 6, 7). Also, it exhibits a moderate affinity for α1 
adrenergic and histamine H1 receptors (8, 9). 
Aripiprazole has a linear pharmacokinetic within the dose ranges of 5-30 mg/day (10). It 
is metabolized by the liver by dehydrogenation (CYP2D6), hydroxylation (CYP2D6), 
and N-dealkylation (CYP3A isozymes). It has an active metabolite, dehydro-aripiprazole, 
representing about 40% of aripiprazole AUC in plasma at steady state. Dehydro-
aripiprazole has an affinity for dopamine D2 receptors similar to aripiprazole (11). The 
peak plasma concentration of aripiprazole occurs within 3 to 5 hours post dose. The mean 
volume of distribution at steady state is 4.9 L/kg. Half-life of aripiprazole is 75 hours for 
CYP2D6 extensive metabolizers and 146 hours for poor metabolizers while for dehydro-
aripiprazole it is about 94 hours (1). Aripiprazole and its metabolite are widely bound to 
plasma proteins, primarily to albumin (12). 
According to drug label (1), most common adverse drug reactions (ADRs) to aripiprazole 
are akathisia and nausea with an incidence of 3% among patients. Other ADRs produced 
by aripiprazole are: agitation, insomnia, anxiety, extrapyramidal disorders, somnolence, 
headache, blurred vision, vomiting, constipation, fatigue, tachycardia and postural 
hypotension (1). 
In general, aripiprazole has a better safety profile than other atypical antipsychotics; it has 
a lower rate of extrapyramidal symptoms, weight gain or hyperprolactinemia (10).  
The role of aripiprazole on corrected QT (QTc) prolongation is contradictory. Even 
though aripiprazole is thought not to affect QTc interval (13, 14) several cases of long 
QTc after aripiprazole treatment have been described (15, 16). Furthermore, there is no 
“Thorough QT/QTc Study” (a study to determine if a drug can prolong QTc) of 
aripiprazole available in the literature. 
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Several studies have shown that it is less likely to produce long QT syndrome (10) than 
other antipsychotics like pimozide (17), haloperidol, ziprasidone and clozapine (18, 19). 
Moreover, evidence of its effects on heart rate and blood pressure remains unclear (12, 
20). 
Our aim was to evaluate the relationship between pharmacokinetics and safety profile of 
aripiprazole, and also, to study its influence on the electrocardiogram and the blood 
pressure in healthy subjects receiving a single dose. 
Materials and methods  
Study population 
One hundred and fifty-seven healthy volunteers (89 men and 68 women) were enrolled 
in six bioequivalence clinical trials performed at the Clinical Trial Unit of Hospital 
Universitario de la Princesa. These trials were conducted following approval by the 
Research Ethics Committee of Hospital de la Princesa (Madrid, Spain), duly authorized 
by the “Agencia Española de Medicamentos y Productos Sanitarios” (AEMPS) and under 
the guidelines of Good Clinical Practice. All the volunteers gave written informed consent 
for the study. 
Subjects who fulfilled all of the inclusion criteria and none of the exclusion criteria were 
included in the study. The inclusion criteria were: age from 18 to 55 years-old, subjects 
free from any organic or psychic conditions, normal vital signs and electrocardiogram, 
no clinically significant abnormalities in hematology, biochemistry, serology, and urine 
test. Exclusion criteria were: subjects who have received prescribed pharmacological 
treatment in the last 15 days or any kind of medication in the 48 hours prior to receiving 
the study medication, body mass index (BMI) outside the 18.5-30.0 range, smokers, 
history of sensitivity to any drug, pregnant women or lactose intolerance.  
Study design and procedures 
All the clinical trials were phase I, oral single dose, randomized, open-label, two periods, 
two sequences, crossover, single-center studies with blind determination of the plasma 
concentrations of aripiprazole by the responsible analyst. In half of the trials the 
volunteers received aripiprazole 10 mg tablets, while in the other half the volunteers 
received aripiprazole 10 mg orodispersible tablets. In the first period, each volunteer 
received a single dose of one formulation of aripiprazole (test or reference). In the second 
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period after a washout period of 28 days, each volunteer received the same dose of the 
other formulation. Volunteers fasted from 10 hours before until 5 hours after drug 
administration. For tablets, each administration was with at least 240 ml (8 ounces) of 
water and for orodispersible tablets, previous to drug administration volunteers rinsed 
their mouth with 20 ml of water. In all the studies the reference formulation was Abilify® 
(Otsuka Pharmaceutical Laboratories Europe). 
Blood samples were collected in 6 ml sterile EDTA-K2 tubes. Samples were centrifuged 
at 3500 rpm (1900 g) for 10 minutes and then, plasma was collected and stored at -20ºC 
until its shipment to the accredited external laboratory which determined plasma 
concentrations of aripiprazole. These concentrations were measured by reverse phase 
high performance liquid chromatography coupled to a tandem mass spectrometry detector 
(LC/MS/MS), with a lower limit of quantification of 0.5 ng/ml. The method involved 
solid-phase extraction procedure with strong cation-exchange and reversed phase 10 mg 
plates. Chromatographic separations were performed on a reversed-phase column 
(Zorbax SB-C18, 4.6 x 50 mm, 3.5μm, from Agilent Technologies). The mobile phase 
was ammonium formate 1 mM, 0.1% formic acid prepared in Milli-Q water: methanol 
(42:58 v/v). The chromatographic separation was isocratically performed at room 
temperature at a flow-rate of 1.00 mL/min. 
Pharmacodynamic analysis 
Blood pressure was measured in supine position using an automatic monitor at pre-dose, 
0.5, 2, 4, 6 and 8 hours after dosing. Also, a 12-lead electrocardiogram was obtained at 
pre-dose, 4 and 8 hours post dose. As the QT interval has an inverse relationship to heart 
rate, it might be corrected for heart rate; for this purpose we used Bazett's correction 
formula (21). According to the ICH E14 clinical guidance (22), we considered corrected 
QT (QTc) interval prolongation an absolute QTc interval > 450 ms or a change from 
baseline in QTc interval >30 ms. 
Pharmacokinetic analysis  
Pharmacokinetic parameters were estimated by non-compartmental analysis using 
WinNonlin Professional, version 2.0. (Pharsight Corporation, USA). The maximum 
plasma concentration (Cmax) and time to reach the maximum plasma concentration (Tmax) 
were obtained directly from raw data. The total area under the curve from administration 
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to infinity (AUC0−∞) was calculated as the sum of AUC0−t and the residual area (Ct divided 
by ke, with Ct as the last measured concentration and ke as the apparent terminal 
elimination rate, which was estimated by log-linear regression from the terminal portion 
of the log-transformed concentration-time plots). Half-life (t1/2) was calculated by 
dividing 0.693 by ke. 
The total drug clearance adjusted for bioavailability (Cl/F) was calculated by dividing the 
dose by the AUC0−∞ and adjusting for weight (Cl/FW). AUC and Cmax were adjusted for 
dose and weight and logarithmically transformed for statistical analysis. 
Safety and tolerability assessments 
The safety and tolerability of aripiprazole was assessed by clinical evaluation of adverse 
events (AEs) and other parameters including: vital signs, physical examinations and 12-
lead ECGs. During the development of the study, volunteers were asked if they had 
suffered any AE and also, those AEs spontaneously notified by the volunteer were 
recorded. Karch and Lasagna criteria (23) were used to determine causality. On the basis 
of these criteria, AEs can be classified as: definite, probable, possible, unlikely and 
unrelated. Only those AEs which were definite, probable, or possible, were considered as 
adverse drug reactions (ADRs) and taken into account for the statistical analysis. Intensity 
(mild, moderate and severe), time sequence and outcome of AEs were also recorded. 
According to the drug label (1), ADRs were classified using “System Organ Class” (SOC) 
allocation as: general (asthenia, back pain), cardiovascular (hypotension, QTC 
prolongation, syncope and tachycardia), gastrointestinal (gastroenteritis, nausea/vomiting 
and abdominal pain), genitourinary (polyuria), neurological (dizziness, headache, hiccups 
and somnolence), psychiatric (nightmares, insomnia and nervousness) and respiratory 
(shortness of breath). 
Statistical analysis 
Statistical analysis was carried out using the SPSS 15.0 software (SPSS Inc., Chicago, IL, 
EEUU); p values less than 0.05 were considered statistically significant. We have 
analyzed the data of both formulations (reference and test formulations of tablets and 
orodispersible tablets) together due to the fact that they have proved to be bioequivalent. 
For the statistical analysis of pharmacokinetics and ADRs we have considered data from 
each period separately. For the statistical analysis of the ADRs, it was only considered 
whether or not an ADR had developed, not including the number of times that this ADR 
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took place. Pharmacokinetic data were logarithmically transformed for data analysis, 
except Tmax, in accordance with EMA guidelines (24). The corrected Pearson χ²-test was 
applied to compare the incidence of ADRs between men and women and between age 
groups (above or below 30 years old). Also, we determined the influence of the 
pharmacokinetics on ADRs using t-test. We used the same test to study if 
pharmacokinetics parameters differ between age groups. We perform a logistic regression 
to study the influence of age and sex in the development of ADRs. Furthermore, to study 
the capacity of AUC and Cmax, to discriminate patients with ADRs and nauseas/vomiting 
ROC curves were plotted and sensitivity and specificity computed. 
We evaluated whether sex had influence on pharmacokinetics and pharmacodynamic 
parameters (SBP, DBP, QTc and HR) using t-test. Correlation between AUC, Cmax and 
concentration of aripiprazole (at 4 h and 8 h) and decrease in BP and increase in QTC and 
HR was analyzed by lineal regression.  
 
Results 
Demographic characteristics 
We analyzed 157 healthy volunteers (89 men and 68 women). Demographic data are 
shown in table 1. Average age was similar between men and women. However, men had 
a greater weight, height and BMI than women. 
There were volunteers who participated in more than one clinical trial: 1 subject 
participated in four, 1 subject participated in three and 17 subjects participated in two 
clinical trials. 121 subjects only participated in one clinical trial. There were 17 subjects 
who only completed one period. 
Pharmacokinetic analysis 
Mean and standard deviation of pharmacokinetic parameters are included in table 2. We 
found statistically significant differences between men and women in some 
pharmacokinetic parameters, even after adjusting for weight. AUC, Cmax, T1/2 and Vd/W 
were higher in women, as table 2 shows. Also, we analyzed if there was a relationship 
between subject withdrawal and higher values of AUC and Cmax. Volunteers who dropped 
out due to vomiting (after administration) or other ADRs (N=11) showed a tendency in 
having higher values of AUC (1759.3± 658.5 ng·h/mL vs 1605.2±412.1 ng·h/mL; 
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P=0.988) and Cmax (56.4±17.4 ng/mL vs 48.3±10.5 ng/mL; P=0.068) than those 
volunteers who did not leave the study or those who left the study for personal reasons 
(N=146). However, these findings were not statistically significant. Volunteers older than 
30 years old had higher levels of T1/2 (62.2±28.3 vs 50.3±21.6; P=0.044) and Vd/W 
(4.6±0.8 vs 4.1±0.9; P=0.004) compared to those younger than 30 years old, but there 
were no differences in AUC and Cmax. 
Pharmacodynamics 
As table 3 shows aripiprazole has a blood pressure lowering effect: systolic blood pressure 
(SBP) decreased a maximum mean of 9.3 mmHg and diastolic blood pressure (DBP) 
decreased a mean of 6.2 mmHg. There was a significant inverse relationship between 
AUC and SBP (nonstandardized β coefficient= -0.005, P= 0.005) and DBP 
(nonstandardized β coefficient= -0.002, P= 0.012). Similarly, there was a statistically 
significant increase in heart rate at 4 h (4.5 lpm, P=0.001) and even higher at 8 h (12.1 
lpm, P<0.001) compared with pre-dose value. We found a directly proportional 
relationship between AUC and heart rate (nonstandardized β coefficient= 0.005, P= 
0.024). We did not find relationship between Cmax and SBP, DBP and heart rate. 
There was a 9.1 ms increase in QTc interval from baseline to 4 and 8 hours post-dose 
(Table 3). Following EMA criteria (22), at 4 h post-dose there were 18 volunteers with 
long QTc and at 8 h post-dose there were 24 volunteers with long QTc. A QTc interval 
prolongation > 500 ms or an increase from baseline > 60 ms is considered an increased 
risk of Torsade de Pointes (25, 26). There were 3 subjects in which increase of QTc from 
baseline was >60 ms. In our study, aripiprazole plasmatic concentrations were not related 
to increase in QTc interval at 4 h (nonstandardized β coefficient= 0.239, P= 0.265) or 8 
h post-dose (nonstandardized β coefficient= 0.247, P= 0.329.). There was also no 
relationship between long QTc interval and higher concentrations of aripiprazole at the 
time of ECG, AUC and Cmax values. 
In relation to sex, there were significant differences in SBP, DBP, QTc and HR at all 
measured times. Blood pressure was higher in men than in women, while heart rate and 
QTc interval were higher in women than in men, as table 3 shows. However, the 
pharmacodynamic effect of aripiprazole was similar in men and women.  
Adverse drug reactions 
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During the course of the study there were no severe, serious or life threatening AEs. 19 
volunteers (12.1%, 14 women and 5 men) dropped out of the study for different reasons; 
including vomiting within 2 hours after drug administration (47.4%), personal reasons 
(42.1%) or other ADRs (10.5%). In these cases, only pharmacokinetic parameters of the 
first period were considered. Study withdrawal was associated with sex, with a dropout 
rate higher in women than in men (20.6% vs 5.6%; P =0.006). 
A total of 108 volunteers (68.8%) suffered at least one ADR, being the most frequently 
reported: dizziness (38.9%), nausea/vomiting (29.9%) and headache (18.5%). Using SOC 
allocation, the most frequent were neurological (51.0%) and gastrointestinal ADRs 
(31.8%). 
In general, ADRs incidence was greater among women (77.9% vs 61.8% in men, 
P=0.037). Particularly, gastrointestinal ADRs were more frequent in women than in men 
(45.6% vs 21.3%, P =0.002), including nausea/vomiting (42.6% vs 20.2%, P=0.003). 
Our results demonstrate a significant association between pharmacokinetics and ADRs. 
Volunteers who suffered at least one ADR or gastrointestinal ADRs had higher AUC and 
Cmax values than those who did not, as shown in table 4. Also, we found higher AUC and 
Cmax values in volunteers who suffered nausea/vomiting, but these results only were 
statistically significant for Cmax (Table 4). 
To establish the best cutoff to discriminate volunteers in risk of ADRs from AUC and 
Cmax values, ROC curve were plotted (Figure 1). Area under ROC curve were 
significantly higher than 0.5 (P < 0.001 in both); AUC, 0.631 (95%CI: 0.572 – 0.691) 
and Cmax, 0.613 (95%CI:  0.553 – 0.673). The best cutoff for AUC was 1570.3 ng·h/mL 
(sensitivity, 55.8%, specificity, 70.3%) and for Cmax 55.61 ng/mL (sensitivity, 36.8%, 
specificity, 82.3%). In multivariate logistic regression models age was not significantly 
associated to ADRs. Since nausea/vomiting were more frequent in women, Odds Ratio 
2.789 (95%CI: 1.510 – 5.154), cutoff were studied separately for men and women. Area 
under ROC curve to predict nausea/vomiting from AUC and Cmax values, were 
significantly higher than 0.5 for men (P = 0.010 and P = 0.002, respectively); AUC, 0.680 
(95%CI: 0.549 – 0.812) and Cmax 0.721 (95%CI:  0.617 – 0.825, but area under ROC 
curve were not significantly higher than 0.5 for women (AUC, P = 0.460 and Cmax, P = 
0.687). For men, the best cutoff for AUC was 1688.9 ng·h/mL (sensitivity, 68.4%, 
specificity, 75.8%) and for Cmax the best cutoff was 43.88 ng/mL (sensitivity, 94.7%, 
specificity, 51.6%). 
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The percentage of subjects with ADRs did not differ statistically between young (≤30 
years), 70.1%, and older volunteers (> 30 years), 63.3% (P=0.514). 
Discussion 
Sex influence on pharmacokinetics 
The pharmacokinetic parameters obtained in our study are similar to those published in 
the literature (27, 28) and shown in the drug label (1). Sex differences were observed in 
the pharmacokinetics of aripiprazole. AUC, Cmax, T1/2 and Vd/W were higher in women 
than in men. These results are consistent with information in the drug label (1), which 
states that: “Cmax and AUC of aripiprazole are 30 to 40% higher in women than in men. 
These differences, however, are largely explained by differences in body weight (25%) 
between men and women”. However, we found statistically significant differences after 
adjusting all the parameters for weight. 
Influence of sex on drug pharmacokinetics is a quite well-known aspect. There are 
different factors causing these differences, such as hormonal changes and differences in 
body weight (29, 30). Women present a higher Vd/W than men, due to their highest fat 
percentage (30). These findings are discrepant with a previous study analyzing different 
antipsychotics, in which differences between sex and plasmatic concentrations were only 
found with clozapine and olanzapine but not with aripiprazole (31). Moreover, other 
studies did not find influence of sex on plasma concentration of aripiprazole (32, 33). 
These different results could be explained by the differences in study design (these 
clinical trials are multiple dose, whereas our study is single dose).  
Pharmacodynamics 
In our study aripiprazole increased heart rate and decreased blood pressure. These results 
are consistent with other study on which aripiprazole increased heart rate from baseline 
(mean increase of 4 bpm vs 1 bpm after placebo). This could be due to a compensatory 
response to a decrease of blood pressure (34). Orthostatic hypotension is a known side 
effect of many antipsychotic drugs, although some cases of hypertension after 
aripiprazole treatment have been described (35, 36). 
QTc prolongation is a known risk factor of sudden death. Many studies have reported the 
effect of antipsychotics on QTc prolongation (37, 38), being the most common 
thioridazine (withdrawn from the Spanish market in 2005) and ziprasidone (39). The 
effect of aripiprazole on the QTc interval in electrocardiograms remains unclear. We 
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described an increase on QTc interval after the administration of aripiprazole. In a study 
with psychiatric patients the QTc interval decreased 6.94 ms from baseline to the end of 
treatment (40). Another study reported a reduction in QTc with aripiprazole (41). 
However, in a recently controlled crossover study for 90 drugs with 59,467 subjects (42) 
aripiprazole showed a mean QTc prolongation of 7.6 ms, that is similar to our data. In 
addition, Torsade de Pointes (a form of ventricular tachycardia) was reported in a patient 
without history of cardiovascular risk after administration of 2.5 mg of aripiprazole (43). 
This is the first study to demonstrate a relationship between AUC of aripiprazole and 
change in SBP, DBP and HR. Surprisingly, it was not related to QTC prolongation, maybe, 
because it also depends on the concentrations of the active metabolite. 
Sex influence on pharmacodynamics 
Differences in blood pressure and ECG regarding sex are well known (44, 45, 46, 47). 
Longer QTc in women may be due to genetic or hormonal differences (48). In a study 
performed in psychiatric patients with 4 antipsychotics (including aripiprazole) sex 
differences in QTc interval were only observed with olanzapine (49). In another study 
performed in psychiatric patients and healthy volunteers (50) a sex effect in the QT 
interval in healthy volunteers was reported, but not in the case of patients. These results 
agree with those found in our population, where healthy female volunteers had higher 
QTc values than males, but the effect of aripiprazole was similar in both groups. 
Adverse drug reactions 
Several studies have reported the influence of sex on ADRs (51, 52, 53). These 
differences might be related with differences in the exposure of women and men to drugs 
(53, 54). Indeed, in our study the AUC and Cmax values were higher in women. 
There are few published studies that examine the influence of pharmacokinetics on the 
safety of aripiprazole. A previous study (10) showed that there is not relationship between 
ADRs and pharmacokinetic parameters of aripiprazole. However, in a review (55) there 
appears to be a correlation between aripiprazole plasma levels and D2/D3 receptor 
occupancy. Greater values of AUC and Cmax could lead to a greater D2/D3 receptor 
occupancy and therefore, to a greater percentage of ADRs. In addition, in this review two 
ranges of aripiprazole levels were described for ADRs. In the first one (110-249 ng/ml) 
ADRs were mild or absent. In the other one (210-335 ng/ml) the ADRs ranged from 
moderate to severe. These findings are similar to our results that show a relationship 
between AUC and Cmax and ADRs/gastrointestinal reactions.  
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Study limitations 
Our study includes six single dose bioequivalence clinical trials with healthy volunteers. 
The main limitation of our study is the impossibility to evaluate neither the efficacy of 
the drug nor the chronic ADRs (extrapyramidal symptoms, weight gain or diabetes). Also, 
CYP2D6 genotyping was not performed but it is no relevant for evaluating the 
relationship between concentrations and adverse reactions. On the contrary, our study 
allows controlling typical confounding factors of studies performed on psychiatric 
patients such as pathologic characteristics of the disease, concomitant therapy and the 
motivation of patients. It is important to take into account that these results must be 
interpreted with caution because pharmacokinetics, pharmacodynamics, and tolerability 
could be different in psychotic patients. Larger studies are needed to increase the 
statistical power of these results. 
Conclusions 
Pharmacokinetic of aripiprazole is affected by sex. AUC, Cmax, T1/2 and Vd/W are higher 
in women than in men. ADRs were more common in women, specially nausea and 
vomiting. Subjects with higher values of AUC and Cmax are more likely to suffer these 
ADRs. Aripiprazole lowers blood pressure and raises heart rate and QTc interval. AUC 
was related to decrease in blood pressure and increase in heart rate, but not to QTc 
increase. Sex is an influential factor on blood pressure and electrocardiogram parameters. 
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Table 1. Baseline demographic characteristics of the volunteers, expressed as mean ± 
standard deviation. *p≤0.01 and **p≤0.001 vs men. 
N (%) Age (years) Weight (kg) Height (m) BMI (kg/m2) 
All 157 (100%) 26.1±7.5 70.0±11.7 1.71±0.09 23.9±2.9 
Men 89(56.7%) 25.1±6.4 75.1±9.7 1.76±0.07 24.5±2.6 
Women 68(43.3%) 27.5±8.6 62.6±9.7** 1.64±0.06** 23.1±3.1* 
 
 
 
Table 2. Pharmacokinetic parameters of aripiprazole following a single oral dose of 10 
mg.*p≤0.05, and **p≤0.001 vs men, after adjusting for weight. 
Pharmacokinetic parameters All Men Women 
AUC (ng·h/mL) 1616.0±432.7 1552.7±396.2 1698.9±466.3* 
Cmax (ng/mL) 48.8±11.2 46.5±9.8 51.9±12.3
* 
Tmax(h) 3.2 ± 1.7 3.0±1.6 3.4±1.7 
T1/2(h) 52.6 ± 23.4 46.9±16.4 60.0±28.7
** 
Vd/W (L/kg) 4.2 ± 0.9 3.9±0.7 4.6±0.9
** 
Cl/W (mL/h·kg) 63.6± 23.1 64.3±19.5 62.7±27.1 
 
 
  
19 
 
Table 3. Effects of aripiprazole on systolic (SBP) and diastolic blood pressure (DBP), 
heart rate (HR) and corrected QT (QTc) interval, expressed as mean±standard deviation. 
*p≤0.05, **p≤0.01 and ***p≤0.001 compared with pre-dose. +p<0.05, ++p≤0.01 and 
+++p≤0.001 compared with men, at the same time. 
 
 Sex Pre-dose Post-dose 
   0,5h 2h 4h 6h 8h 
SBP 
(mmHg) 
Men 120.5 ± 10.1 
114.1 ± 
8.5*** 
111.9 ± 
10.5*** 
113.8 ± 8.8*** 116.6 ± 9.5 116.3 ± 8.9* 
Women 
111.3 ± 
10.0+++ 
105.3 ± 
9.3**+++ 
101.0 ± 
8.7***+++ 
104.0 ± 
8.0***+++ 
105.1 ± 
8.5***+++ 
105.2 ± 
9.0***+++ 
Total 116.5 ± 11.0 
110.3 ± 
9.8*** 
107.2± 11.1*** 109.6 ± 9.8*** 
111.6 ± 
10.7*** 
111.5 ± 
10.5*** 
DBP 
(mmHg) 
Men 66.6 ± 7.4 64.0 ± 6.8 60.4 ± 7.1*** 60.8 ± 6.2*** 60.0 ± 5.5*** 60.3 ± 5.6*** 
Women 
62.8 ± 
6.4+++ 
60.3 ± 5.5+++ 57.0 ±  5.5***++ 
57.8 ± 
4.7***+++ 
57.2 ± 
4.0***+++ 
57.4 ± 
4.3***+++ 
Total 65.0 ± 7.2 62.4 ± 6.5** 58.9 ± 6.7*** 59.5 ± 5.8*** 58.8 ± 5.1*** 59.0 ± 5.3*** 
HR(bpm) 
Men 60.6 ± 9.7   64.9 ± 10.2*  72.9 ± 11.8*** 
Women 
66.0 ± 
10.0+++ 
  
70.6 ± 
11.3*+++ 
 
77.9 ± 
11.2***+++ 
Total 62.9 ± 10.0   67.4 ± 11.0***  75.0± 11.8*** 
QTC (ms) 
Men 392.5 ± 16.8   400.9 ± 21.1*  401.5 ± 21.6** 
Women 
410.0 ± 
16.9+++ 
  
420.0 ± 
24.9*+++ 
 
419.4 ± 
21.5*+++ 
Total 400.1 ± 18.9   
409.2 ± 
24.6*** 
 
409.2 ± 
23.3*** 
 
 
 
Table 4. Association between pharmacokinetic parameters (AUC and Cmax) and adverse 
drug reactions (ADRs).*p≤0.05 and**p≤0.001 vs “No”. N=number of drug 
administrations. 
  N (%) AUC (ng·h/mL) Cmax(ng/ml) 
ADRs 
No 175 (51.8%) 1495.2±365.0 46.6±11.3 
Yes 163 (48.2%) 1677.9±453.0** 51.5±13.1** 
Nausea/vomiting 
No 280 (82.8%) 1561.3±412.8 48.0±12.4 
Yes 58 (17.2%) 1689.2±437.5 53.4±12.0* 
Gastrointestinal 
reactions 
No 277 (82.0%) 1553.8±408.3 47.8±12.2 
Yes 61 (18.0%) 1717.1±445.4* 53.9±12.3** 
 
 
20 
 
Figure 1. ROC curves for AUC and Cmax to discriminate subjects with adverse drug 
reactions (ADRs). 
 
 
 
 
